Skip to main content

Table 2 Characteristics of 274 children in the Nordic JIA cohort according to school absence at the eight-year study visita

From: Participation in school and physical education in juvenile idiopathic arthritis in a Nordic long-term cohort study

Characteristics at the eight-year visit n Absence ≤1 day (n = 228) Absence > 1 day (n = 46) OR (95% CI) P-value
Female, n (%) 274 148 (64.9) 32 (69.6) 1.2 (0.6–2.4) 0.545
Age disease onset, years 274 5.2 (2.3–9.2) 4.6 (2.3–8.7) 1.0 (0.9–1.1) 0.440
BMI 234 19.5 (17.3–21.6) 19.8 (17.2–24.8) 1.1 (1.0–1.2) 0.117
Cumulative joint count 274 5 (2–10) 11 (5–14) 1.0 (1.0–1.0) 0.007
Active joints 274 0 (0–0) 0 (0–1) 1.5 (1.2–1.9) 0.002
Physician GA 190 0.0 (0.0–0.5) 1.0 (0.2–2.1) 7.1 (2.7–18.5) < 0.001
Patient/parent GA 213 0.0 (0.0–0.6) 1.2 (0.0–2.5) 3.5 (1.8–6.8) < 0.001
Pain VAS 217 0.0 (0.0–0.8) 1.4 (1.0–3.5) 3.5 (1.9–6.5) < 0.001
CHAQ 274 0.0 (0.0–0.0) 0.3 (0.0–0.6) 10.1 (4.4–23.1) < 0.001
CHQ-PF50, PhS 159 53.4 (47.9–57.3) 41.8 (32.1–50.4) 0.9 (0.8–0.9) < 0.001
CHQ-PF50, PsS 159 54.9 (47.5–60.1) 54.3 (49.7–58.4) 1.0 (0.9–1.1) 0.792
DMARDs, n (%) 274 72 (31.6) 27 (58.7) 1.8 (1.3–2.7) 0.002
JADAS10 174 0.4 (0.0–2.2) 3.5 (0.6–6.1) 1.3 (1.2–1.5) < 0.001
Not in remission, n (%) 267 126 (56.8) 42 (93.3) 10.7 (3.2–35.5) < 0.001
ESR mm/hour 193 7.0 (4.0–11.0) 8.0 (4.0–13.0) 1.0 (1.0–1.1) 0.110
CRP mg/liter 201 0.0 (0.0–5.0) 0.0 (0.0–5.0) 1.0 (1.0–1.1) 0.168
RF positive 147 3 (2.6) 2 (6.3) 2.5 (0.4–15.6) 0.330
HLA-B27 positive 264 45 (20.6) 15 (32.6) 1.9 (0.9–3.7) 0.081
ANA positive 273 57 (25.1) 7 (15.2) 0.5 (0.2–1.3) 0.154
  1. aPatient-/ proxy-reported school absence because of JIA during the preceding 2 months of the eight-year study visit with univariate logistic regression. Values are the median (interquartile range, IQR), unless indicated otherwise, OR Odds ratio, CI Confidence interval, GA Global assessment, VAS Visual analogue scale, CHAQ Childhood health assessment questionnaire, CHQ-PF50 Child health questionnaire parent form, PhS Physical summary score, PsS Psychological summary score, DMARDs Disease-modifying antirheumatic drugs including biologics used at the final study visit, Not in remission Not in remission off medication according to the Wallace preliminary criteria [21], ESR Erythrocyte sedimentation rate, CRP C-reactive protein, RF Rheumatoid factor, assessed twice with at least 3 months interval, HLA-B27 Human leucocyte antigen, ANA Antinuclear antibody, assessed twice with at least 3 months interval